Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that
often precedes the onset of classic motor symptoms by decades. There is no standardized
algorithm for managing constipation in this patient population, nor are there dedicated
treatments. Studies suggest that constipation can affect quality of life to a significant
degree, in many cases just as much as motor symptoms. There is an unmet need for effective
treatment options for constipation in this patient population. The goal of this study is to
determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation
in patients with PD.